文献速递肾移植

预存供者特异性HLA抗体在活体与尸体肾移植中的多中心研究

Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-06-18

该多中心回顾性研究纳入2012至2015年德国18个移植中心4233例连续肾移植,评估预存供者特异性HLA抗体(DSA)的预后价值。结果显示预存DSA与移植物生存率降低相关,活体移植风险比尸体移植更高,且弱DSA(<3000 MFI)也影响生存。

要点

  • 预存DSA与移植物生存率降低相关,活体移植风险高于尸体移植。
  • ABO血型不合移植独立于DSA与更差移植物生存相关。
  • DSA≥3000 MFI与6个月内抗体介导排斥反应发生率更高相关。

核心结论

  • 预存DSA与肾移植移植物丢失风险增加相关,活体移植中风险高于尸体移植。
  • 弱DSA(<3000 MFI)也与更差移植物生存相关,且活体移植中关联更强。

研究设计与样本

  • 回顾性多中心研究,纳入2012至2015年德国18个移植中心4233例连续肾移植。
  • 多数中心采用逐步移植前抗体筛查:微珠阵列试验及单抗原试验鉴别阳性样本。
  • 检测针对HLA-A、-B、-C、-DRB1和-DQB1的DSA,回顾性收集临床结局与协变量。

主要发现

  • 预存DSA与更低总体移植物生存相关:活体捐赠风险比2.53(95%CI 1.49-4.29;P<0.001),尸体捐赠风险比1.59(95%CI 1.21-2.11;P=0.001)。
  • ABO血型不合移植与更差移植物生存相关(风险比2.09;95%CI 1.33-3.27;P=0.001),独立于DSA。
  • DSA针对class 1、class 2或两者之间无差异。
  • 按DSA <3000 MFI和≥3000 MFI分层后生存曲线重叠;尸体捐赠中,DSA<3000 MFI倾向与3个月和长期移植生存降低相关,DSA≥3000 MFI仅与长期移植生存更差相关。
  • 活体捐赠中,仅强DSA与最初3个月移植物生存降低相关,但弱和强DSA均与长期移植物生存降低相关;6个月内抗体介导排斥反应发生率更高仅与DSA≥3000 MFI相关。

临床怎么用

  • 移植前应筛查预存DSA,即使弱DSA(<3000 MFI)也需关注其与移植物丢失风险的关联。
  • 活体移植中预存DSA的预后影响可能大于尸体移植,评估时应考虑移植类型。

局限性

  • 回顾性研究设计。
  • 数据来自德国移植中心,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The prognostic value of preformed donor-specific HLA antibodies (DSA), which are only detectable by sensitive methods, remains controversial for kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The outcome of 4233 consecutive kidney transplants performed between 2012 and 2015 in 18 German transplant centers was evaluated. Most centers used a stepwise pretransplant antibody screening with bead array tests and differentiation of positive samples by single antigen assays. Using these screening results, DSA against HLA-A, -B, -C, -DRB1 and -DQB1 were determined. Data on clinical outcome and possible covariates were collected retrospectively. RESULTS: Pretransplant DSA were associated with lower overall graft survival, with a hazard ratio of 2.53 for living donation (95% confidence interval [95% CI], 1.49 to 4.29; P<0.001) and 1.59 for deceased donation (95% CI, 1.21 to 2.11; P=0.001). ABO-incompatible transplantation was associated with worse graft survival (hazard ratio, 2.09; 95% CI, 1.33 to 3.27; P=0.001) independent from DSA. There was no difference between DSA against class 1, class 2, or both. Stratification into DSA <3000 medium fluorescence intensity (MFI) and DSA ≥3000 MFI resulted in overlapping survival curves. Therefore, separate analyses were performed for 3-month and long-term graft survival. Although DSA <3000 MFI tended to be associated with both lower 3-month and long-term transplant survival in deceased donation, DSA ≥3000 MFI were only associated with worse long-term transplant survival in deceased donation. In living donation, only strong DSA were associated with reduced graft survival in the first 3 months, but both weak and strong DSA were associated with reduced long-term graft survival. A higher incidence of antibody-mediated rejection within 6 months was only associated with DSA ≥3000 MFI. CONCLUSIONS: Preformed DSA were associated with an increased risk for graft loss in kidney transplantation, which was greater in living than in deceased donation. Even weak DSA <3000 MFI were associated with worse graft survival. This association was stronger in living than deceased donation.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ziemann M, Altermann W, Angert K, et al. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study. Clin J Am Soc Nephrol. 2019. PMID: 31213508. doi:10.2215/CJN.13401118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。